Low-Molecular-Weight Chondroitin Sulfate via Enzymatic Depolymerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing low molecular weight chondroitin sulfate face challenges such as high molecular weight, complex structure, low bioavailability, poor oral absorption, and unstable efficacy, with insufficient pharmacodynamic studies on specific molecular weight ranges and compositions.
Innovation Solution
A method involving enzymatic depolymerization using chondroitin sulfate lyase derived from Escherichia coli or Bacillus subtilis to produce low molecular weight chondroitin sulfate with controlled average molecular weight below 1000 Dalton and narrow distribution, comprising chondroitin sulfate disaccharide and tetrasaccharide as main components, optimized through specific reaction conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high molecular weight chondroitin sulfate is used, then the structure is stable and biological activities are diverse, but the apparent viscosity is high, cell membrane penetration is difficult, and bioavailability is low
Solution Approach 1:
The patent applies segmentation by breaking down high molecular weight chondroitin sulfate into low molecular weight oligosaccharides (mainly disaccharides and tetrasaccharides with average molecular weight 800-1200 Da). This segmentation resolves the contradiction by maintaining the core disaccharide structure (GlcA-GalNAc) that provides biological activity while reducing molecular weight to improve absorption and bioavailability.
2Productivity
If acid hydrolysis is used to degrade chondroitin sulfate, then low molecular weight products are obtained, but many impurities are generated and sulfonic groups fall off causing environmental pollution
Solution Approach 1:
The patent replaces the chemical hydrolysis method (acid or base) with an enzymatic method using chondroitinase AC II. This substitution resolves the contradiction by providing mild reaction conditions that selectively cleave β-1,4 glycosidic bonds without causing sulfonic group detachment or generating harmful impurities, thus eliminating environmental pollution issues.
3Object-affected harmful factors
If enzymatic depolymerization is used, then reaction conditions are mild and pollution is reduced, but the enzyme source has low specificity and efficiency
Solution Approach 1:
The patent optimizes enzymatic reaction parameters including pH (6.0-8.0), temperature (30-40°C), enzyme-to-substrate ratio, and reaction time to maximize the efficiency and specificity of chondroitinase AC II. These parameter changes resolve the contradiction by enabling the enzyme to work under optimal conditions, achieving high catalytic efficiency while maintaining the environmental benefits of enzymatic depolymerization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves stable production of low molecular weight chondroitin sulfate with improved bioavailability, enhanced efficacy in repairing chondrocytes and treating joint injuries, and reduced dosage requirements for therapeutic applications, while maintaining high purity and specificity.
Implementation Method 1
enzymatic depolymerization with chondroitin sulfate lyase
Implementation Method 2
enzymatic depolymerization will not cause the destruction of sulfonic acid group
Data Source
AI summary
The invention relates to a low molecular weight sulfate chondroitin and a preparation method thereof. A low molecular weight chondroitin sulfate with the average molecular weight of less than 1000 Dalton can be obtained by a production process of chondroitin sulfate lyase degradation, deproteinization, filtration and sterilization and drying using macromolecular sulfate chondroitin as a raw material. The low molecular weight Chondroitin sulfate has a narrow molecular weight distribution range, the ratio of chondroitin sulfate disaccharide is 43˜60% and the ratio of chondroitin sulfate tetrasaccharide is 30˜45%, the sum of chondroitin sulfate disaccharide and chondroitin sulfate tetrasaccharide is more than 87%, the total oligosaccharide content of low molecular weight chondroitin sulfate is more than 97% and the protein content is less than 0.5%; Compared with the general market macromolecule chondroitin sulfate, the product has more remarkable repair effect at the concentration of 50˜100 μg/mL on chondrocytes damaged by 1 mM hydrogen peroxide, with strong repair ability and repair rate of 14%˜23%. The low molecular weight chondroitin sulfate can be used to treat joint injury and is an important raw material for medical products, health care products, cosmetics and food.